Given that cancer cells utilize multiple pathways to evade immune elimination and extensive cross-interactions among these pathways, combinational therapy against PD-L1, Tbsax1, and/or IL-6 may offer better therapeutic outcome. This evidence concerns the gene IL6 and cancer.